Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RPRX.O
stocks logo

RPRX.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
829.22M
+11.76%
1.315
+14.2%
825.00M
-1.67%
1.160
+9.73%
714.00M
-1.79%
1.310
+14.85%
Estimates Revision
The market is revising Upward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 9.02%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.32%
In Past 3 Month
Stock Price
Go Up
up Image
+9.02%
In Past 3 Month
Wall Street analysts forecast RPRX.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX.O is 43.50 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast RPRX.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX.O is 43.50 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.160
sliders
Low
38.00
Averages
43.50
High
54.00
Current: 39.160
sliders
Low
38.00
Averages
43.50
High
54.00
TD Cowen
TD Cowen
Buy
to
Hold
downgrade
2025-11-17
New
Reason
TD Cowen
TD Cowen
Price Target
2025-11-17
New
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Royalty Pharma to Hold from Buy without a price target after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
Goldman Sachs
NULL
to
Buy
initiated
$42
2025-09-30
Reason
Goldman Sachs
Price Target
$42
2025-09-30
initiated
NULL
to
Buy
Reason
Goldman Sachs initiated coverage of Royalty Pharma with a Buy rating and $42 price target, which represents 20% upside. The company offers investors a way to gain exposure to a portfolio of biopharma royalty streams without incurring biotech's "volatility and binary risks," the analyst tells investors in a research note. The firm believes Royalty is in the early stages of a portfolio expansion that is underappreciated in the context of a large, growing total addressable market for royalty funding.
Citi
Buy
maintain
$40 -> $42
2025-07-22
Reason
Citi
Price Target
$40 -> $42
2025-07-22
maintain
Buy
Reason
Citi raised the firm's price target on Royalty Pharma to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Morgan Stanley
Terence Flynn
Overweight
maintain
$51 -> $54
2025-07-10
Reason
Morgan Stanley
Terence Flynn
Price Target
$51 -> $54
2025-07-10
maintain
Overweight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Royalty Pharma to $54 from $51 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Morgan Stanley
Overweight
initiated
$51
2025-05-16
Reason
Morgan Stanley
Price Target
$51
2025-05-16
initiated
Overweight
Reason
Morgan Stanley resumed coverage of Royalty Pharma with an Overweight rating and $51 price target. The firm cites se the company's diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Royalty Pharma PLC (RPRX.O) is 7.82, compared to its 5-year average forward P/E of 10.01. For a more detailed relative valuation and DCF analysis to assess Royalty Pharma PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
10.01
Current PE
7.82
Overvalued PE
13.26
Undervalued PE
6.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
10.38
Current EV/EBITDA
9.50
Overvalued EV/EBITDA
12.50
Undervalued EV/EBITDA
8.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
6.38
Current PS
39.16
Overvalued PS
10.11
Undervalued PS
2.66
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 100.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RPRX.O News & Events

Events Timeline

(ET)
2025-11-07
09:38:39
Royalty Pharma Executes Block Trade of 14.244 Million Shares at $40.00 Each
select
2025-11-07
08:00:58
Royalty Pharma Executes Block Trade of 14.244 Million Shares at $40.00 to $40.78 Price Range
select
2025-11-05 (ET)
2025-11-05
07:09:43
Royalty Pharma increases FY25 portfolio receipts forecast to $3.2B-$3.25B
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-12NASDAQ.COM
Upcoming Ex-Dividend Dates for Royalty Pharma, Cencora, and MMM

  • Upcoming Ex-Dividend Dates: On 11/14/25, Royalty Pharma plc (RPRX), Cencora Inc (COR), and 3M Co (MMM) will trade ex-dividend, with respective dividends of $0.22, $0.60, and $0.73 scheduled for payment in December.

  • Expected Price Adjustments: Following the ex-dividend date, RPRX shares are expected to open 0.56% lower, COR by 0.16%, and MMM by 0.43%, based on their recent stock prices.

  • Dividend Yield Estimates: The estimated annualized yields for the companies are 2.26% for Royalty Pharma, 0.66% for Cencora, and 1.73% for 3M, reflecting their historical dividend stability.

  • Current Trading Performance: As of Wednesday trading, shares of Royalty Pharma, Cencora, and 3M are up approximately 1.1%, 0.1%, and 0.6%, respectively.

[object Object]
Preview
9.5
11-06NASDAQ.COM
Royalty Pharma Plc Reports Decline in Q3 Earnings

  • Earnings Decline: Royalty Pharma plc reported a profit drop in the third quarter, with earnings of $288.22 million ($0.67 per share) compared to $543.99 million ($1.21 per share) last year.

  • Revenue Increase: Despite the decline in earnings, the company's revenue increased by 7.9% to $609.29 million, up from $564.69 million in the previous year.

[object Object]
Preview
4.5
11-06Benzinga
Stocks Recover as Eli Lilly Soars to 14-Month Peak: What’s Driving Market Activity on Wednesday?

  • Market Recovery: Wall Street rebounded on Wednesday after a selloff in AI stocks, driven by solid corporate earnings and indications that the Federal Reserve may be close to cutting interest rates.

  • Employment Report: The ADP National Employment Report indicated that private employers added 42,000 jobs in October, surpassing expectations and showing some resilience in the labor market, although hiring remains below robust levels.

  • Stock Performance: Major indices saw gains, with the S&P 500 up 0.9% and the Nasdaq 100 rising 1.1%, while notable stock movements included Eli Lilly and Advanced Micro Devices posting significant increases.

  • Crypto and Commodities: Cryptocurrency markets rebounded, with Bitcoin rising to nearly $104,000, and commodities like gold and silver also saw price increases, while crude oil prices fell.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Royalty Pharma PLC (RPRX.O) stock price today?

The current price of RPRX.O is 39.16 USD — it has increased 0 % in the last trading day.

arrow icon

What is Royalty Pharma PLC (RPRX.O)'s business?

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

arrow icon

What is the price predicton of RPRX.O Stock?

Wall Street analysts forecast RPRX.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX.O is 43.50 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Royalty Pharma PLC (RPRX.O)'s revenue for the last quarter?

Royalty Pharma PLC revenue for the last quarter amounts to 609.29M USD, increased 7.90 % YoY.

arrow icon

What is Royalty Pharma PLC (RPRX.O)'s earnings per share (EPS) for the last quarter?

Royalty Pharma PLC. EPS for the last quarter amounts to 0.67 USD, decreased -44.63 % YoY.

arrow icon

What changes have occurred in the market's expectations for Royalty Pharma PLC (RPRX.O)'s fundamentals?

The market is revising Upward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 9.02%.
arrow icon

How many employees does Royalty Pharma PLC (RPRX.O). have?

Royalty Pharma PLC (RPRX.O) has 99 emplpoyees as of November 18 2025.

arrow icon

What is Royalty Pharma PLC (RPRX.O) market cap?

Today RPRX.O has the market capitalization of 22.60B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free